Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC
Abstract
To the Editor: In the MARIPOSA trial, Yang et al. (Oct. 30 issue) 1 report superior overall survival with amivantamab–lazertinib as compared with osimertinib in patients with untreated EGFR (epidermal growth factor receptor)–mutated advanced non–small-cell lung cancer (NSCLC). Despite promising results, clinical translation is limited (Table 1). Dual EGFR and MET inhibition is mechanistically rational, yet resistance profiling was not adequately investigated. MET amplification is a canonical mechanism of osimertinib resistance, but systematic sequencing of circulating tumor DNA or tumor tissue was not performed at the time of disease progression. 2,3 Without monitoring, whether amivantamab delays resistance or merely shifts its spectrum . . .
Fields of Study & Subjects
Lung Cancer Treatments and Mutations
Colorectal Cancer Treatments and Studies
Lung Cancer Research Studies
Publication details
- Journal / source
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Volume
- 394
- Issue
- 9
- Pages
- 933–936
- Publication date
- 25 February 2026
- Language
- EN